中危及高危前列腺癌近距离放疗推量后的结局:SFRO近距离放疗组的一项回顾性双中心研究
这项回顾性双中心研究纳入2006年至2019年接受外照射放疗联合高剂量率近距离放疗推量的709例中危或高危前列腺癌患者,中位随访62个月,5年生化控制率总体为87.5%,中危和高危分别为91%和85%,5年总生存率为94%,晚期≥2级泌尿生殖或胃肠道毒性分别见于36例(5%)和9例(1.3%)。
要点
- 中位外照射放疗剂量为46 Gy(35-50),中位高剂量率近距离放疗推量剂量为14 Gy(10-20)。
- 5年生化控制率总体87.5%,中危91%,高危85%。
- 5年生化及临床无复发生存率、无转移生存率和局部控制率分别为83%、90%和97%。
核心结论
- 该双中心分析显示高剂量率近距离放疗推量作为外照射放疗补充手段具有疗效和耐受性。
研究设计与样本
- 回顾性研究纳入2006年至2019年两家中心所有接受外照射放疗联合高剂量率近距离放疗推量的中危或高危前列腺癌患者,最终分析709例,其中中危277例(有利型170例、不利型107例),高危432例。
主要发现
- 中位外照射放疗剂量为46 Gy(35-50),中位高剂量率近距离放疗推量剂量为14 Gy(10-20)。
- 中位随访62个月后,5年生化控制率总体为87.5%,中危为91%,高危为85%。
- 5年生化及临床无复发生存率、无转移生存率和局部控制率分别为83%、90%和97%。
- 5年总生存率为94%。
- 晚期≥2级泌尿生殖毒性见于36例(5%),晚期≥2级胃肠道毒性见于9例(1.3%)。
局限性
- 原文指出因其他中心随访时间短,仅分析了两家中心的709例患者。
- 原文结论认为需要进一步改进,如联合新型内分泌药物或新的近距离放疗-放疗分割方案,以进一步改善结局和治疗比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Radiotherapy dose escalation improves biochemical control in intermediate- or high-risk prostate cancer. Brachytherapy boost was shown to further improve biochemical control compared to radiotherapy alone in three randomized trials. The SFRO brachytherapy group sought to evaluate the efficacy and toxicity of BT-boost for intermediate and high-risk prostate cancer in real life, and to determine prognostic factors for efficacy and toxicity. MATERIAL AND METHOD: A retrospective study was conducted, including all patients with intermediate- or high-risk prostate cancer treated with a combination of external beam radiotherapy (EBRT) and high dose-rate brachytherapy boost (HDR-BB), from 2006 until December 2019 at two centers. Patient characteristics, initial disease, treatment and follow-up were collected. RESULTS: 709 patients from two centers were analyzed given a short follow-up in the other centers. Out of those, 277 were intermediate risk (170 favorable and 107 unfavorable) and 432 were high risk. The median EBRT and HDR-BB doses were 46 Gy (35-50) and 14 Gy (10-20). After a median follow-up of 62 months, biochemical control at 5 years was 87.5 % for the overall population, 91 % and 85 % for intermediate- and high-risk cancers, respectively. At 5 years, biochemical and clinical relapse-free survival, metastasis-free survival and local control rates were 83 %, 90 % and 97 % respectively. 5-years overall survival was 94 %. Late grade 2 or higher GU or GI toxicity was found in 36 patients (5 %) and 9 patients (1.3 %). CONCLUSION: This bicenter analysis shows the efficacy and tolerability of HDR-BB as a complement to external radiotherapy. Further improvements such as combination with new hormonal agents or new brachytherapy-radiotherapy fractionation regimens are warranted to improve further the outcomes and therapeutic ratio.
引用
- Ka K, Schiappa R, Terlizzi M, et al. Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: A retrospective bicenter study by the SFRO brachytherapy group. Radiother Oncol. 2023. PMID: 36638842. doi:10.1016/j.radonc.2022.109460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。